During the inspection of an Indian active pharmaceutical ingredient manufacturer, European GMP inspectors were met with severe deficiencies. Read here, which violations of GMP principles for production, laboratory and handling of reference samples led to a Non-Compliance Report.
The Indian drug manufacturer Kim Chemicals received an FDA Warning Letter in October 2017. During an FDA inspection, it was criticised that not all medicinal products and the active substances they contained had been tested for compliance with the specifications. Find out more about the Kim Chemicals FDA Warning Letter.
At the end of last year, the FDA published a revision draft for their guideline "Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products" which is supposed to take account of the current standards of risk assessment and the submitted data of past change notifications.